Regulatory polymorphisms of MSH6, MSH2, FBXO11, and PPP1R21 genes affect survival of patients with immunotherapy-treated lung cancer.

J Immunother Cancer · 2025 · PMC12406856 · PMID 40889797

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

nearly significantp value=6.3× 10 −8actually significant

Interestingly, the OS genome-wide analysis identified 10 nearly significant variants (p value=6.3× 10 −8 ) on chromosome 2, in complete LD with each other ( figure 2 ).

also in 2,605 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Regulatory polymorphisms of &lt;i&gt;MSH6&lt;/i&gt;, &lt;i&gt;MSH2&lt;/i&gt;, &lt;i&gt;FBXO11,&lt;/i&gt; and &lt;i&gt;PPP1R21&lt;/i&gt; genes affect survival of patients with immunotherapy-treated lung cancer.

The sentences

Regulatory polymorphisms of <i>MSH6</i>, <i>MSH2</i>, <i>FBXO11,</i> and <i>PPP1R21</i> genes affect survival of patients with immunotherapy-treated lung cancer.